Source: International Congress 2018 – Clinical trials in COPD: new results
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Psallidas (Gothenburg, Sweden), C. Astbury (Barcelona, Spain), L. Jimenez (Barcelona, Spain), U. Walby Hamren (Gothenburg, Sweden), B. Seoane (Barcelona, Spain), M. Malice (Barcelona, Spain), V. Balaguer (Barcelona, Spain), A. Lei (Barcelona, Spain), A. Aggarwal (Boston, United States of America), D. Singh (Manchester, United Kingdom). Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients. 1656

Member's Comments

No comment yet.

Related content which might interest you: Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500μg to 1000μg are dose-linear in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002 Aspirin inhalation treatment for COPD patients: Preliminary studies on PK and inflammatory biomarkers Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007 Effect of a single dose of formoterol and tiotropium in exercise tolerance in COPD patients: preliminary data Source: Eur Respir J 2003; 22: Suppl. 45, 405s Year: 2003 Pharmacokinetic (PK) and pharmacodynamic (PD) data for inhaled and intranasal corticosteroids (CS) reassessed using a physiological PK/PD model Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Differences between pharmacokinetics of ciclesonide-active principle and budesonide following repeated dose inhalations Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Once-daily NVA237 improves lung function in COPD patients: Pooled results of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Population pharmacokinetics of nebulized arformoterol in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006 Superior spirometric efficacy of single dose formoterol compared to single dose salmeterol during the first hour post-dose in moderate and severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 57s Year: 2001 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Pharmacodynamic effects of nebulised bronchodilator combinations Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007 Clinical synergism of LABA/LAMA combinations in COPD patients Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017